Clinical Trials Directory

Trials / Completed

CompletedNCT01610362

Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
50 (actual)
Sponsor
Queen Saovabha Memorial Institute · Academic / Other
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

Dosage of rabies immune globulin was calculated from the victim's body weight, then the amount of rabies immune globulin would be injected as much as possible to all of the wounds. Increase dosage of rabies immune globulin was needed in situation of multiple severe bite-wounds especially among children whose had lower body weight than adults. Our study would be conducted in order to determine whether the increase dosage of rabies immune globulin would interfere with the protective antibody levels against rabies.

Detailed description

* Controlled trial study. * All 50 volunteers who had never had rabies immunization would be enrolled and designated into 2 groups. group 1 : 15 Healthy volunteers age 18 - 60 yr who were attacked by mammals, possible exposed to rabies and had WHO category III exposure, all receive standard post - exposure rabies treatment with 5-dose intramuscular rabies vaccine on day 0,3,7,14,28 and 20 IU/kg of human rabies immune globulin (HRIG). group 2 : 35 Healthy volunteers age 18 - 60 yr receive 5-dose intramuscular rabies vaccine on day 0,3,7,14,28 and 40 IU/kg of human rabies immune globulin (HRIG). 5 cc - Blood would be drawn from all volunteers before vaccination and on day 14, 28 and 90 for rabies neutralizing antibody titers (RNab). The GMTs of RNab among both groups would be analyzed and compared.

Conditions

Interventions

TypeNameDescription
BIOLOGICALHuman Rabies Immune GlobulinHRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0

Timeline

Start date
2012-06-01
Primary completion
2018-04-01
Completion
2018-04-01
First posted
2012-06-04
Last updated
2018-04-09

Locations

1 site across 1 country: Thailand

Source: ClinicalTrials.gov record NCT01610362. Inclusion in this directory is not an endorsement.